51Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Singapore
Neuroscience Intelligence
Singapore neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #33 of 50 · Data maturity A · Research score 32.3 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
14Recruiting trials
49Publications
47Institutions
Executive interpretation
Singapore ranks #33 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC54 recruiting
National Neuroscience Institute41 recruiting
National University Hospital, Singapore31 recruiting
National Healthcare Group, Singapore30 recruiting
Novartis Pharmaceuticals21 recruiting
National University of Singapore20 recruiting
Eisai Inc.22 recruiting
Hoffmann-La Roche21 recruiting
AbbVie20 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.20 recruiting
Disease activity
Alzheimers8trials
Stroke7trials
Parkinsons5trials
Autism4trials
Epilepsy3trials
Neuro Oncology2trials
Dementia Other2trials
Other Psychiatry2trials
Anxiety1trials
Pain Neuropathy1trials
Research institutions
Duke-NUS Medical SchoolOpenAlexlinked institution
Ngee Ann PolytechnicOpenAlexlinked institution
National Cancer Centre SingaporeOpenAlexlinked institution
Singapore Centre for Environmental Life Sciences EngineeringOpenAlexlinked institution
National Heart Centre SingaporeOpenAlexlinked institution
INSEADOpenAlexlinked institution
Singapore Management UniversityOpenAlexlinked institution
Genome Institute of SingaporeOpenAlexlinked institution
Nanyang Technological UniversityOpenAlexlinked institution
SingHealthOpenAlexlinked institution
Clinical evidence trail
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06857955A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsACTIVE_NOT_RECRUITING
NCT06702293Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology PatientsRECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)ACTIVE_NOT_RECRUITING
NCT05503264A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidACTIVE_NOT_RECRUITING
NCT04239859Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque PsoriasisNOT_YET_RECRUITING
Research evidence trail
PUBMEDGlycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex.2026-12-15
PUBMEDRetrosigmoid craniotomy surgical guide: The way forward for precise exposure of the transverse-sigmoid sinuses.2026-11-01
PUBMEDα-Synuclein Seeds Amplification Assays for Parkinson's Disease and Related Synucleinopathies.2026-11-01
PUBMEDAssociation of stenosis and arterial remodeling with cerebral hemodynamics and cognition.2026-10-08
PUBMEDCHCHD2 and CHCHD10 promoted autophagic clearance of protein aggregates via GABARAPs.2026-10-01
PUBMEDSleep fragmentation and heightened inflammation: A latent profile subtype predicting nine-year major depressive disorder severity in the MIDUS study.2026-10-01
PUBMEDExcitation-inhibition imbalance links amyloid pathophysiology to cognition in non-demented individuals.2026-10-01
PUBMEDGlobal, regional, and national burden of road injuries 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.2026-09-01
PUBMEDUse of Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: A Systematic Review of Current Clinical Evidence.2026-09-01
PUBMEDPCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications.2026-08-18
PUBMEDPrevalence and clinical correlates of lifetime suicide attempts in 2114 patients with bipolar disorder: Findings from a multi-center Asian consortium study.2026-08-15
PUBMEDNF1 Leucine Rich Domain-Derived Extracellular Vesicles Remodel the Glioblastoma Immune Microenvironment via an ADAM17-Associated Inflammatory Program.2026-08-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.